|
Idelalisib in Waldenström macroglobulinemia: high incidence of hepatotoxicity
|
|
Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience
|
|
Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis
|
|
Renal disease related to Waldenström macroglobulinaemia: incidence, pathology and clinical outcomes
|
|
Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia
|
|
Histological transformation to diffuse large B-cell lymphoma in patients with Waldenström macroglobulinemia
|
|
Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome
|
|
Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia
|
|
Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia
|
|
Recommendations for the diagnosis and initial evaluation of patients with waldenstrom's macroglobulinaemia a task force from the 8th international workshop on waldenstrom's macroglobulinaemia
|
|
miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth
|
|
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib
|
|
DUAL NAMPT AND BTK TARGETING LEADS TO SYNERGISTIC KILLING OF WALDENSTROM`S MACROGLOBULINEMIA CELLS REGARDLESS OF MYD88 AND CXCR4 SOMATIC MUTATIONS STATUS
|
|
Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia
|
|
To select or not to select? The role of B-cell selection in determining the MYD88 mutation status in Waldenström Macroglobulinaemia
|
|
Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia
|
|
Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia
|
|
Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.
|
|
Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders
|
|
Atrial fibrillation associated with Ibrutinib in Waldenström's macroglobulinemia
|
